Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response

MeSH terms

• Amyloidosis / diagnosis*
• Amyloidosis / etiology*
• Hematologic Neoplasms / etiology*
• Humans
• Janus Kinase 2 / antagonists & inhibitors
• Janus Kinase 2 / genetics
• Janus Kinase Inhibitors / adverse effects
• Janus Kinase Inhibitors / therapeutic use
• Kidney Diseases / diagnosis*
• Kidney Diseases / etiology*
• Male
• Middle Aged
• Nitriles
• Primary Myelofibrosis / complications*
• Primary Myelofibrosis / drug therapy
• Primary Myelofibrosis / genetics
• Pyrazoles / adverse effects
• Pyrazoles / therapeutic use
• Pyrimidines
• Tomography, X-Ray Computed